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rameters, showing correlation with the clinical response
achieved. There were significant changes in major compo-
nents of QLQ-C30 in pts who achieved clinical response.
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Administrative health care databases are increasingly
used as a source of data for economic studies in cancer.
In order to adjust for disease severity, several investiga-
tors have utilized ICD-9 codes indicating metastases as a
proxy for cancer staging. OBJECTIVE: To determine the
validity of using ICD-9-CM codes indicating metastases
as a proxy to classify lung cancer patients by stage of dis-
ease. METHODS: This retrospective database analysis
used diagnosis codes to classify subjects to either local-
ized or advanced stage disease and then compared this
classification to the tumor registry staging, which was
considered as the “gold standard”. Study subjects in-
cluded all lung cancer patients treated at an academic in-
stitution during 1996–97 who were also members of a
large insurance company. Data was derived from inpa-
tient cancer-related claims linked with the institution’s
tumor registry data. Advanced stage disease (stages II to
IV) was defined by claims indicating lymph node involve-
ment or metastases (ICD-9 codes 196-199.1). The tumor
registry staging of the disease for these patients were clus-
tered into two groupings, stages 0–I (localized) and stages
II–IV (advanced). RESULTS: Tumor registry entries were
identified for 85.7% of patients. The crude concordance
between the claims and tumor registry classifications was
74.2% (Kappa coefficient  0.4848). The positive pre-
dictive value of identifying localized disease utilizing
ICD-9 coding was 57.6%,while the predictive value of a
negative test was 91%. The sensitivity and specificity for
dichotomized disease stage was 86.4% and 68.2% re-
spectively. CONCLUSIONS: For a population of lung
cancer patients in an academic institution, the use of
ICD-9 coding was associated with modest predictability
for disease staging. The use of ICD-9 coding as a proxy
for disease staging in economic evaluations should be ex-
ecuted with caution.
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OBJECTIVES: Lung cancer is a leading cause of morbid-
ity and mortality. Chemotherapy is one of the main treat-
ment options but its availability in the UK is limited in
comparison to other countries, is inconsistent across geo-
graphical regions, with many patients receiving only pal-
liative care. The present study reports results of an eco-
nomic evaluation of Gemzar (one of the newer agents
available) and best supportive care (BSC) relative to BSC
in the treatment of advanced NSCLC. BSC relates to all
forms of care which are non-curative in intent excluding
chemotherapy. METHODS: The study is undertaken
from the perspective of the UK NHS. Data were ex-
tracted from a comparative trial undertaken in the UK
(Anderson et al in 1997). Cost estimates are based on:
chemotherapy and associated infusion, hospitalisations,
health care professional visits, concomitant medications,
radiotherapy and terminal palliative care. Resource utili-
sation data from the clinical trial were combined with
unit-cost data from various UK sources. Costs are pre-
sented in 2000 price levels and the time horizon for their
estimation is one year; hence discounting was unneces-
sary. Treatment effectiveness is measured by progression-
free survival and tumour response. Extensive sensitivity
analysis was also performed. RESULTS: Total treatment
cost per patient in the Gemzar/BSC arm was estimated at
£5,502 and at £3,861 for the BSC arm, the difference at-
tributed mainly to the drug (Gemzar) and its administra-
tion costs. The intervention arm had lower radiotherapy/
concomitant medication costs, but this did not offset the
drug acquisition cost. Progression free life years and
overall tumour response rates were 0.789 and 18.5% in
the Gemzar/BSC arm and 0.474 and 0% in the BSC arm.
The incremental cost-per-progression-free-life-year gained
in Gemzar/BSC relative to BSC is £5,228 and the incre-
mental cost-per-tumour-response £8,873. Changes in the
key variables varied the above ratios between £3,000 and
£23,000. CONCLUSIONS: The economic evaluation
presented above shows that Gemzar/BSC is a cost-effec-
tive therapy for advanced NSCLC relative to BSC alone.
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OBJECTIVES: Pancreatic cancer is a significant and in-
creasing cause of morbidity and mortality in the UK.
Treatment with chemotherapy has shown to improve
symptoms and survival of patients. Gemzar is licenced
for treatment of pancreatic cancer in the UK. This study
reports on an economic evaluation of Gemzar relative to
5-FU, a commonly used regimen for advanced pancreatic
cancer patients in the UK. METHODS: The perspective
is that of the UK-NHS. Data were derived from a clinical
